Aptevo Therapeutics (APVO) vs Revelation Biosciences (REVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aptevo Therapeutics is the larger company by market cap ($3.3 million vs $3.1 million), about 1.1 times the size. On valuation, Aptevo Therapeutics trades at a lower trailing P/E (0.0x vs 0.2x for Revelation Biosciences).
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | APVO | REVB |
|---|---|---|
| Share price | $1.80 | $0.7739 |
| Market cap | $3.26M | $3.08M |
| 1-day change | -2.17% | -6.55% |
| P/E ratio (TTM) | 0.03 | 0.17 |
| EPS (TTM) | $66.96 | $4.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.12 | $6.24 |
| 52-week low | $1.37 | $0.75 |
| Distance from 52-week high | -94.57% | -87.60% |
| Average volume | 93.62K | 39.03K |
| Shares outstanding | 1.81M | 3.98M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Revelation Biosciences trades at a higher earnings multiple (0.2x vs 0.0x trailing P/E).
APVO vs REVB FAQ
Which is bigger, Aptevo Therapeutics or Revelation Biosciences?
Aptevo Therapeutics (APVO) is larger, with a market capitalization of $3.26M compared with $3.08M for Revelation Biosciences (REVB).
Which has the lower P/E ratio, APVO or REVB?
APVO has the lower trailing P/E at 0.0, versus 0.2 for REVB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Aptevo Therapeutics and Revelation Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.